Trial Profile
A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Zanubrutinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors BeiGene
- 05 Nov 2020 Status changed from active, no longer recruiting to completed.
- 12 Jun 2020 Pooled analysis from 4 studies (NCT04170283; NCT03145064; NCT02569476; NCT03520920) published in the BeiGene Media Release.
- 12 Jun 2020 According to an BeiGene media release, pooled analysis from 4 studies (NCT04170283; NCT03145064; NCT02569476; NCT03520920) were presented at the 25th European Hematology Association (EHA) Virtual Congress.